Complement-mediated thrombotic microangiopathy (TMA) in the form of atypical hemolytic uremic syndrome (aHUS) has emerged as an immune complication of systemic adeno-associated virus (AAV) gene transfer that was unforeseen based on nonclinical studies. Understanding this phenomenon in the clinical setting has been limited by incomplete data and a lack of uniform diagnostic and reporting criteria. While apparently rare based on available information, AAV-associated TMA/aHUS can pose a substantial risk to patients including one published fatality. Reported cases were originally limited to pediatric Duchenne muscular dystrophy patients receiving micro- or mini-dystrophin transgenes via AAV9 but have subsequently been reported in both pediatric and adult patients across a range of disorders, transgenes, promoters, and AAV capsid types. This article provides an introduction to the complement system, TMA and aHUS, and anticomplement therapies, then presents clinical reviews of AAV-associated TMA/aHUS cases that have been reported publicly. Finally, exploration of risk factors and current and future mitigation approaches are discussed.
GavriilakiE, AnagnostopoulosA, MastellosDC. Complement in thrombotic microangiopathies: Unraveling Ariadne’s thread into the labyrinth of complement therapeutics. Front Immunol, 2019; 10:337; doi: 10.3389/fimmu.2019.00337
3.
GülhanB, ÖzaltınF, FidanK, et al.Management of pediatric hemolytic uremic syndrome. Turk J Pediatr, 2024; 66(1):1–16; doi: 10.24953/turkjped.2023.596
LekA, AtasE, HesterleeSE, et al.Meeting report: 2022 Muscular Dystrophy Association summit on ‘safety and challenges in gene transfer therapy’. J Neuromuscul Dis, 2023; 10(3):327–336; doi: 10.3233/jnd-221639
6.
Costa-VerderaH, UnzuC, ValeriE, et al.Understanding and tackling immune responses to adeno-associated viral vectors. Hum Gene Ther, 2023; 34(17–18):836–852; doi: 10.1089/hum.2023.119
ChandDH, ZaidmanC, AryaK, et al.Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A case series. J Pediatr, 2021; 231:265–268; doi: 10.1016/j.jpeds.2020.11.054
18.
YazakiK, SakumaS, HikitaN, et al.Child neurology: Pathologically confirmed thrombotic microangiopathy caused by onasemnogene abeparvovec treatment for SMA. Neurology, 2022; 98(19):808–813; doi: 10.1212/wnl.0000000000200676
19.
GuillouJ, de PellegarsA, PorcheretF, et al.Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv, 2022; 6(14):4266–4270; doi: 10.1182/bloodadvances.2021006419
20.
PrabhuN, SaylamE, LouisC, et al.Thrombotic microangiopathy (TMA): A potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for spinal muscular atrophy (SMA) (5483). Neurology, 2020; 94(15_supplement):5483; doi: 10.1212/WNL.94.15_supplement.5483
FrieseJ, GeitmannS, HolzwarthD, et al.Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec -a single centre experience. J Neuromuscul Dis, 2021; 8(2):209–216; doi: 10.3233/jnd-200593
33.
ServaisL, HortonR, SaadeD, et al;261st ENMC workshop study group. 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands. Neuromuscul Disord, 2023; 33(11):884–896; doi: 10.1016/j.nmd.2023.09.008
34.
ServaisL, DayJW, De VivoDC, et al.Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: Findings from the RESTORE registry. J Neuromuscul Dis, 2024; 11(2):425–442; doi: 10.3233/jnd-230122
35.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78(12):6381–6388; doi: 10.1128/jvi.78.12.6381-6388.2004
36.
WangL, BellP, SomanathanS, et al.Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther, 2015; 23(12):1877–1887; doi: 10.1038/mt.2015.179
37.
RawlsA, DiviakBK, SmithCI, et al.Pharmacotherapeutic approaches to treatment of muscular dystrophies. Biomolecules, 2023; 13(10)1536; doi: 10.3390/biom13101536
38.
YinX, WangQ, ChenT, et al.CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy. Int J Clin Exp Pathol, 2015; 8(3):3069–3075.
39.
HathoutY, LiangC, OgundeleM, et al.Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy. Sci Rep., 2019; 9(1):12167; doi: 10.1038/s41598-9
40.
VukojicicA, DelestréeN, FletcherEV, et al.The classical complement pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep, 2019; 29(10):3087–3100.e7; doi: 10.1016/j.celrep.2019.11.013
41.
ZhouH, HongY, ScotoM, et al.Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect. J Clin Invest, 2022; 132(21):e153430; doi: 10.1172/JCI153430
42.
SzunyogovaE, ZhouH, MaxwellGK, et al.Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci Rep, 2016; 6:34635; doi: 10.1038/srep34635
43.
LevstekT, VujkovacB, Trebusak PodkrajsekK.Biomarkers of Fabry nephropathy: Review and future perspective. Genes, 2020; 11(9):1091; doi: 10.3390/genes11091091
44.
WijngaardeCA, HuismanA, WadmanRI, et al.Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy. J Neurol Neurosurg Psychiatry, 2020; 91(2):212–214; doi: 10.1136/jnnp-2019-321506
45.
HeoSH, KangE, KimYM, et al.Fabry disease: Characterisation of the plasma proteome pre- and post-enzyme replacement therapy. J Med Genet, 2017; 54(11):771–780; doi: 10.1136/jmedgenet-2017-104704
46.
D’SouzaRS, LevandowskiC, SlavovD, et al.Danon disease: Clinical features, evaluation, and management. Circ Heart Fail, 2014; 7(5):843–849; doi: 10.1161/circheartfailure.114.001105
47.
MameliE, MartelloA, CaporaliA. Autophagy at the interface of endothelial cell homeostasis and vascular disease. FEBS J, 2022; 289(11):2976–2991; doi: 10.1111/febs.15873
48.
ChenM, ZhuangJ, YangJ, et al.Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review. Medicine (Baltimore), 2017; 96(43):e8284; doi: 10.1097/md.0000000000008284
49.
Carrillo-CarrascoN, ChandlerRJ, VendittiCP. Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis, 2012; 35(1):91–102; doi: 10.1007/s10545-011-9364-y
KichulaEA, ProudCM, FarrarMA, et al.Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve, 2021; 64(4):413–427; doi: 10.1002/mus.27363
52.
LichtC, Al-DakkakI, AnokhinaK, et al.Characterization of patients with aHUS and associated triggers or clinical conditions: A global aHUS registry analysis. Nephrology (Carlton), 2024; 29(8):519–527; doi: 10.1111/nep.14304
53.
McAteeCL, LubegaJ, UnderbrinkK, et al.Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open, 2021; 4(2):e2036321; doi: 10.1001/jamanetworkopen.2020.36321
BönnemannCG, BelluscioBA, BraunS, et al.Dystrophin immunity after gene therapy for Duchenne’s muscular dystrophy. N Engl J Med, 2023; 388(24):2294–2296; doi: 10.1056/NEJMc2212912
56.
LekA, WongB, KeelerA, et al.Death after high-dose rAAV9 gene therapy in a patient with Duchenne’s Muscular Dystrophy. N Engl J Med, 2023; 389(13):1203–1210; doi: 10.1056/NEJMoa2307798
